Skip to content

Application of oxelidine in postoperative analgesia

Application of oxelidine in postoperative analgesia in patients with laparoscopic total hysterectomy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099358
Enrollment
Unknown
Registered
2025-03-21
Start date
2025-03-31
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain

Interventions

test group:The test group was configured with oxelidine 20mg and normal saline into 200ml, and was divided into two load doses of oxelidine, 0.75 mg each time, with an interval of 10 min. The total am
control group:The control group was configured with sufentanil 3ug/kg(not more than 100ug) and normal saline were configured into 200ml, the load was 3ml, the PCA dose was 3mL, and the locking time wa

Sponsors

Hefei Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.For patients with laparoscopic total hysterectomy, ASA anesthesia grade I ~ III; 2.Patients aged 18 years<= age <=65 years, BMI:18-28kg/m²; 3.All patients voluntarily participated in this study and signed informed consent before surgery.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to oxelidine and other narcotic drugs; 2. History of postoperative severe nausea and vomiting; 3.Patients with impaired language, intelligence, understanding, and inability to communicate normally; 4.Patients with a history of neuropsychiatric disorders, drug dependence and alcoholism; 5.Patients with serious cardiovascular and cerebrovascular diseases or major organ dysfunction before surgery; 6. Intraoperative conversion to laparotomy. ?7.Patients with abnormal electrocardiogram, such as QT interval > 450ms.

Design outcomes

Primary

MeasureTime frame
painseverity;Patient controlled analgesia press times;The dosage of remedial analgesics used;

Secondary

MeasureTime frame
Recovery situation;Adverse reactions (nausea, vomiting, dizziness, respiratory depression) occurred ;

Countries

China

Contacts

Public ContactBianbian Wang

The Second People's Hospital of hefei

420535127@qq.com+86 155 5635 6835

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026